Table 1.

Cell-cycle analysis of HCD57 cells treated with SP600125 inhibitor for 24 hours




EPO

EPO + vehicle

EPO + 12.5 μM SP600125

EPO + 25 μM SP600125

No EPO
Apoptotic   6.2 ± 0.5   6.1 ± 0.7   10.9 ± 0.2   24.3 ± 2.5   74.4 ± 1.1  
G0/G1  39.6 ± 0.6   39.4 ± 0.2   32.0 ± 0.9   4.7 ± 2.2   10.9 ± 0.6  
S phase   20.9 ± 0.3   20.7 ± 0.4   15.2 ± 1.0   3.8 ± 1.8   6.0 ± 0.8  
G2/M
 
38.6 ± 1.4
 
38.4 ± 0.1
 
46.1 ± 0.2
 
77.0 ± 0.4
 
9.20 ± 0.26
 



EPO

EPO + vehicle

EPO + 12.5 μM SP600125

EPO + 25 μM SP600125

No EPO
Apoptotic   6.2 ± 0.5   6.1 ± 0.7   10.9 ± 0.2   24.3 ± 2.5   74.4 ± 1.1  
G0/G1  39.6 ± 0.6   39.4 ± 0.2   32.0 ± 0.9   4.7 ± 2.2   10.9 ± 0.6  
S phase   20.9 ± 0.3   20.7 ± 0.4   15.2 ± 1.0   3.8 ± 1.8   6.0 ± 0.8  
G2/M
 
38.6 ± 1.4
 
38.4 ± 0.1
 
46.1 ± 0.2
 
77.0 ± 0.4
 
9.20 ± 0.26
 

Values presented are percentage of cells in each phase of cell cycle. Phase of cell cycle was determined by flow cytometry analysis of propidium iodide—stained cells. Error indicates standard deviation of 3 independent samples.

Close Modal

or Create an Account

Close Modal
Close Modal